These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33870698)

  • 1. Studying Homo-oligomerization and Hetero-oligomerization of MDMX and MDM2 Proteins in Single Living Cells by Using In Situ Fluorescence Correlation Spectroscopy.
    Li F; Yu S; Huang X; Dong C; Ren J
    Biochemistry; 2021 May; 60(19):1498-1505. PubMed ID: 33870698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 interacts with MDMX through their RING finger domains.
    Tanimura S; Ohtsuka S; Mitsui K; Shirouzu K; Yoshimura A; Ohtsubo M
    FEBS Lett; 1999 Mar; 447(1):5-9. PubMed ID: 10218570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of p53: a collaboration between Mdm2 and Mdmx.
    Pei D; Zhang Y; Zheng J
    Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
    Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2.
    Singh RK; Iyappan S; Scheffner M
    J Biol Chem; 2007 Apr; 282(15):10901-7. PubMed ID: 17301054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inferring Leading Interactions in the p53/Mdm2/Mdmx Circuit through Live-Cell Imaging and Modeling.
    Heltberg ML; Chen SH; Jiménez A; Jambhekar A; Jensen MH; Lahav G
    Cell Syst; 2019 Dec; 9(6):548-558.e5. PubMed ID: 31812692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mdmx promotes genomic instability independent of p53 and Mdm2.
    Carrillo AM; Bouska A; Arrate MP; Eischen CM
    Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
    ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
    Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
    Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S
    Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2 and MdmX: Partners in p53 Destruction.
    Manfredi JJ
    Cancer Res; 2021 Apr; 81(7):1633-1634. PubMed ID: 34003788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
    Cai X; Yuan ZM
    J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
    Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
    Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
    Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
    EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.